Month: June 2017

Mesothelioma Patients May Have Another Treatment Option With FDA Expanded-Use Approval of Lung Cancer Drug

• Nancy Meredith
• Mesothelioma

In September, MesotheliomaHelp reported that Italian researchers found the response to ceritinib (Zykadia), an anti-cancer drug, was nearly immediate in non-small cell lung cancer patients who were previously treated with chemotherapy and crizotinib (Xalkori). Now, the U.S. Food and Drug Administration has granted approval for expanded use of the drug to include the first-line treatment of NSCLC patients with ALK-positive tumors, opening the door for another treatment option for mesothelioma patients.

Ceritinib, marketed as Zykadia by Novartis, is intended for the treatment of metastatic NSCLC in patients who express the abnormal anaplastic lymphoma kinase (ALK) gene. Approximately 3%-5% of people with NSCLC may test positive for the ALK fusion gene. There is a potential that the marker is also present in certain pleural mesothelioma cases making it a new treatment option for the cancer.

In a May 26 press release from Novartis, the company reports that of the 376 patients in the study, those receiving Zykadia as first-line treatment realized a 16.6 month progression-free survival versus 8.1 months in patients treated with pemetrexed-platinum chemotherapy first-line regimen.

“Today’s approval represents the next step in the development of Zykadia as a treatment option for ALK-positive metastatic NSCLC, bringing this important medication to a patient population where a need still exists,” said Bruno Strigini, CEO, Novartis Oncology.

Pleural mesothelioma patients and oncologists keep a close eye on research and breakthroughs that impact NSCLC patients. Although the two cancers have some differences, including the structure of the tumors, patients often follow a similar treatment protocol.

“At Novartis, we are tireless in our pursuit of developing novel medicines to treat lung cancer, and the first-line approval of Zykadia for ALK-positive metastatic NSCLC illustrates our commitment to cancer patients,” said Strigini.

Close to 3,000 patients are diagnosed with mesothelioma each year in the U.S. Although survival has improved in recent years, there is still no cure for the asbestos-caused cancer.

To find out if you may be a candidate for Zykadia, talk to your medical professional. Visit the Novartis website for more information.

Resilience Can Help Patients & Families Come Back Stronger

• Lisa Hyde-Barrett
• Nurse's Corner

In life, things can happen that shake us up and change the way we look at the world. Trauma, accidents, crimes against us or an unexpected diagnosis of mesothelioma for you or a family member, for example, can change your world in minutes. It is said that how we respond to these events is what makes us stronger. Through these events we often hear the word resilience talked about. What exactly does that mean?

According to Psychology Today, resilience “is that ineffable quality that allows some people to be knocked down by life and come back stronger than ever. Rather than letting failure overcome them and drain their resolve, they find a way to rise from the ashes.”

In the book, “Option B Facing Adversity, Building Resilience, and Finding Joy,” by Sheryl Sandberg and Adam Grant, resilience, grief, and moving forward, are explored.  Ms. Sandberg’s sudden loss of her husband and her coping with her young children’s grief, as well as her own, is documented. In collaboration with Adam Grant, a psychologist and professor at Wharton, who has studied how people find motivation and meaning, Sheryl tells her story. Adam fills in the research on dealing with these issues.

This is an excellent book, easy to read, and is bound to help you at some point in your life. One of the interesting takeaways from the book is that, “more than half of the people who experience a traumatic event report at least one positive change, compared to less than 15% who develop PTSD.” The authors say, “If you don’t see if growth is possible, you’re not going to find it.”

With malignant mesothelioma, unfortunately, loss happens. Everyone’s life and circumstances are different, “Option B” is just one person’s story. We all have our own stories, but it is reassuring to know that others who have endured loss are eventually able to experience joy again. We are not alone as we journey through our lives adventures and challenges.